Lande
Arnold J. Lande, St. Paul, MN US
Patent application number | Description | Published |
---|---|---|
20080295828 | Artificial gills for deep diving without incurring the bends and for scavenging O2 from and dispelling CO2 into water or thin air - The invention provides a system whereby oxygen can be derived from seawater or from thin air at higher altitudes while simultaneously eliminating carbon dioxide from the blood. This allows prolonged underwater liquid breathing at greater depths without suffering from the bends or, alternatively, the ability of workers to breathe underwater or at high altitudes without having to rely upon air tanks or the like. The artificial gill comprises a plurality of concatenated modules each containing a semi-permeable membrane operative to transfer oxygen in a first direction and carbon dioxide in a second direction across the membrane. By providing multiple concatenated interconnected modules, oxygen becomes concentrated to allow breathing thereof. Because the system is connected in series with a person's blood supply, CO | 12-04-2008 |
20100030124 | CHRONIC ACCESS SYSTEM FOR EXTRACORPOREAL TREATMENT OF BLOOD INCLUDING A CONTINOUSLY WEARABLE HEMODIALYZER - A patient wearable, continuously operating extracorporeal pump apparatus which accesses the patient's arterial venous pressure differential by applying external pressure to a subcutaneous graft that has been cannualized to modulate blood flow through an extracorporeal circuit and to drive the pump for delivering a medicament, such as an anticoagulant, to the site of an intravenous cannula to prevent clogging thereof and also to move a dialysate through a circuit, including a dialyzer and a dialysate rejuvenating cartridge, whereby kidney failure can be treated without recourse to prior art hemodialysis machines found in most treatment facilities. With slight modification, the present invention can be used to remove excess fluids from CHF patients, to remove toxins from the blood in those suffering from liver failure and to facilitate administration of insulin to diabetics and/or glucose to those having hypoglycemia. | 02-04-2010 |
20120095402 | Chronic Access System for Extracorporeal Treatment of Blood Including a Continuously Wearable Hemodialyzer - A patient wearable, continuously operating extracorporeal pump apparatus which accesses the patient's arterial venous pressure differential by applying external pressure to a subcutaneous graft that has been cannualized to modulate blood flow through an extracorporeal circuit and to drive the pump for delivering a medicament, such as an anticoagulant, to the site of an intravenous cannula to prevent clogging thereof and also to move a dialysate through a circuit, including a dialyzer and a dialysate rejuvenating cartridge, whereby kidney failure can be treated without recourse to prior art hemodialysis machines found in most treatment facilities. With slight modification, the present invention can be used to remove excess fluids from CHF patients, to remove toxins from the blood in those suffering from liver failure and to facilitate administration of insulin to diabetics and/or glucose to those having hypoglycemia. | 04-19-2012 |
Arnold J. Lande, Northport, MI US
Patent application number | Description | Published |
---|---|---|
20140194804 | Chronic Access System for Extracorporeal Treatment of Blood Including a Continuously Wearable Hemodialyzer - A patient wearable, continuously operating extracorporeal pump apparatus which accesses the patient's arterial venous pressure differential by applying external pressure to a subcutaneous graft that has been cannualized to modulate blood flow through an extracorporeal circuit and to drive the pump for delivering a medicament, such as an anticoagulant, to the site of an intravenous cannula to prevent clogging thereof and also to move a dialysate through a circuit, including a dialyzer and a dialysate rejuvenating cartridge, whereby kidney failure can be treated without recourse to prior art hemodialysis machines found in most treatment facilities. With slight modification, the present invention can be used to remove excess fluids from CHF patients, to remove toxins from the blood in those suffering from liver failure and to facilitate administration of insulin to diabetics and/or glucose to those having hypoglycemia. | 07-10-2014 |
Claudio Lande, Turin IT
Patent application number | Description | Published |
---|---|---|
20140172425 | METHOD FOR SENDING MULTI-MEDIA MESSAGES WITH CUSTOMIZED AUDIO - A system and method of creating a customized multi-media message to a recipient is disclosed. The multi-media message is created by a sender and contains an animated entity that delivers an audible message. The sender chooses the animated entity from a plurality of animated entities. The system receives a text message from the sender and receives a sender audio message associated with the text message. The sender audio message is associated with the chosen animated entity to create the multi-media message. The multi-media message is delivered by the animated entity using as the voice the sender audio message wherein the mouth movements of the animated entity conform to the sender audio message. | 06-19-2014 |
David Lande, Mountain View, CA US
Patent application number | Description | Published |
---|---|---|
20110228404 | Fiber-Coupled Collimator for Generating Multiple Collimated Optical Beams Having Different Wavelengths - An apparatus for providing multiple collimated light beams from optical fibers and the method for producing such beams. The apparatus includes first and second optical fibers that carry light of first and second wavelengths, respectively, a fixture that maintains the fibers in a fixed relationship to one another, and a collimating lens. Light from each of the first and second optical fibers diverges from a face of the fixture. The collimating lens produces first and second collimated light beams that are displaced relative to one another from the light leaving the face. The face of the fixture is positioned to correct for chromatic aberration in the lens. | 09-22-2011 |
Hemraj Mahadeorao Lande, Pune IN
Patent application number | Description | Published |
---|---|---|
20120316238 | NOVEL POLYMOMORPH OF DESVENLAFAXINE BENZOATE - The present invention relates to a novel crystalline form L of (±)-desvenlafaxine benzoate and process for the preparing of the same. Further, the present invention also relates to pharmaceutical composition of novel crystalline form L of desvenlafaxine benzoate and one or more pharmaceutically acceptable excipient. | 12-13-2012 |
Jeffrey Lande, Minneapolis, MN US
Patent application number | Description | Published |
---|---|---|
20090131276 | DIAGNOSTIC KITS AND METHODS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel diagnostic kits and methods employing these genetic markers are used in assessing the risk of SCD, or SCA. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught. | 05-21-2009 |
20090136954 | GENETIC MARKERS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel genetic markers useful in assessing the risk of SCD, or SCA, and kits containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught. | 05-28-2009 |
20100317006 | SCA RISK STRATIFICATION BY PREDICTING PATIENT RESPONSE TO ANTI-ARRHYTHMICS - Genetic tests and methods for treatment based on markers to identify patients suffering from life-threatening ventricular tachy-arrhythmias, such as Ventricular Tachycardias (“VT”) and Ventricular Fibrillation (“VF”) that might lead to Sudden Cardiac Arrest (“SCA”) or Sudden Cardiac Death (“SCD”) are provided. Patients who cannot be sufficiently protected by medication alone, such as those refractory to anti-arrhythmic medication, are identified based on their genotype. The resulting information is used in a diagnostic test to identify and treat those patients who would benefit from the implantation of an Implantable Cardio Defibrillator (“ICD”). | 12-16-2010 |
20110143345 | Genetic Markers for SCD or SCA Therapy Selection - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel genetic markers useful in assessing the risk of SCD or SCA and compositions containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught. | 06-16-2011 |
20110143956 | Diagnostic Kits and Methods for SCD or SCA Therapy Selection - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel diagnostic kits, DNA microarrays, and methods employing these genetic markers are used in assessing the risk of SCD or SCA. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught. | 06-16-2011 |
20120309641 | DIAGNOSTIC KITS, GENETIC MARKERS, AND METHODS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel diagnostic kits and methods employing these genetic markers are used in assessing the risk of SCD, or SCA. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods for assessing the need for an Implantable Cardio Defibrillator (“ICD”) in a patient with computer programmable processors and genetic databases are described. | 12-06-2012 |
20150315644 | METHODS AND COMPOSITIONS FOR SCD, CRT, CRT-D, OR SCA THERAPY IDENTIFICATION AND/OR SELECTION - Compositions, polynucleotides, probes, kits, methods, computer systems, treatment methods and genetic markers useful for assessing the risk of Sudden Cardiac Death (SCD), Sudden Cardiac Arrest (SCA), Ventricular Arrhythmia (VA), or Heart Failure (HF) are provided herein. The compositions, polynucleotides, probes, kits, methods, computer systems, treatment methods and genetic markers of the invention can provide patients selection for those that can be treated with an ICD or CRT-D based on assessing the presence of one or more Single Nucleotide Polymorphisms (SNPs) associated with any one of Sudden Cardiac Death (SCD), Sudden Cardiac Arrest (SCA), Ventricular Arrhythmia (VA), or Heart Failure (HF), and can indicate treatment with certain drugs such as beta-blockers. | 11-05-2015 |
Jyoti Reveji Lande, Maharashtra IN
Patent application number | Description | Published |
---|---|---|
20150336947 | PYRROLOQUINOLINE ALKALOIDS AS ANTIMALARIAL AGENTS AND PROCESS FOR THE PREPARATION THEREOF - The patent provides novel compounds with potential anti-malarial activity and process of synthesis thereof. Further, the process for the synthesis of known antimalarial natural products marinoquinazolinone A-F, aplidiopsamine A and their potential antimalarial analogues is disclosed. | 11-26-2015 |
Nathan Lande, Arlington, VA US
Patent application number | Description | Published |
---|---|---|
20140074731 | SYSTEM AND METHOD FOR AUTOMATED DATA DISCREPANCY ANALYSIS - A method for automatic detection of inconsistencies in an appraisal by extracting data from the appraisal to create component data arranged into a predetermined set of categories and selecting a control identifier to trigger a generation of comparison data. Further, through a comparison between the comparison data and the component data, inconsistencies within the appraisal are identified. | 03-13-2014 |
20140074732 | LOCATION DRIVEN APPRAISAL DATA EXTRACTION, PAST APPRAISAL AND VALUE COMPARISON AND COMPARABLE PROPERTY FINDER - A method for location triggered home evaluation for an electronic device that determines a location of the electronic device and identifies a subject property associated with the location. Further, a set of appraisal information for the subject property that includes a listing of comparable properties determined to be appropriate comparable properties for the subject property is requested. | 03-13-2014 |
20140074733 | PHOTOGRAPH INITIATED APPRAISAL PROCESS AND APPLICATION - The present invention relates to photograph initiated property assessment. In one example, an electronic device performs a photograph initiated property assessment by accessing a photographic assessment itinerary that includes a plurality of target portions for the subject property and a set of image capture requirements for each of the plurality of target portions. Further, when performing the initiated property assessment the electronic device prompts a plurality of image capture requests according to the photographic assessment itinerary while displaying a menu that permits the addition of information to the set of image captures. | 03-13-2014 |
Roberto Lande, Pully CH
Patent application number | Description | Published |
---|---|---|
20120315290 | INHIBITORS OF LL-37 MEDIATED IMMUNE REACTIVITY TO SELF NUCLEIC ACIDS - Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases and/or cancer are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18. | 12-13-2012 |
Roberto Lande, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20110033448 | Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids - Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18. | 02-10-2011 |
Sharad Vasudeorao Lande, Akola IN
Patent application number | Description | Published |
---|---|---|
20150111720 | REGENERATION OF SPENT PARAFFIN DEHYDROGENATION CATALYST - There is provided a method for regenerating a spent dehydrogenation catalyst used in the conversion of n-paraffin to olefin. The method comprises method steps for removing the coke by treating the catalyst with an ozone-oxygen stream followed by an oxygen stream. The catalyst is stabilized by passing a nitrogen stream and the stabilized catalyst is rejuvenated by passing an air-nitrogen stream containing a halogenated hydrocarbon. This is followed by reducing the metal oxide in the catalyst by passing hydrogen-nitrogen stream. | 04-23-2015 |
20150158024 | DEHYDROGENATION CATALYST FOR HYDROCARBONS AND METHOD OF PREPARATION THEREOF - The present disclosure relates to a dehydrogenation catalyst composite comprising at least one alumina support impregnated with at least one layer of at least one alkaline earth metal element and at least one layer comprising at least one catalytic metal element, at least one group VIA element and optionally, at least one halogen element. The present disclosure also relates to a process for preparation of the dehydrogenation catalyst composite. | 06-11-2015 |
Sharad Vasuderao Lande, Akola IN
Patent application number | Description | Published |
---|---|---|
20140323785 | CATALYST COMPOSITE FOR DEHYDROGENATION OF HYDROCARBONS AND METHOD OF PREPARATION THEREOF - The present invention provides a dehydrogenation catalyst composite that is capable of providing a dehydrogenated hydrocarbon product characterized by a bromine number of at least 19. for hydrocarbons. The dehydrogenation catalyst of the present invention comprises a nano-sized complex containing a Group VIII component; a group IVA component and a sulfur containing capping agent; an alkali component; a halogen component; and a support with an inner core of alpha alumina and an outer layer comprising a mixture of gamma alumina and delta alumina. | 10-30-2014 |
Stig Lande, Sarpsborg NO
Patent application number | Description | Published |
---|---|---|
20120128962 | Decking - Decking comprises: a support selected from the group consisting of: polymeric materials; marine engineering polymers, fibre reinforced polymers, polymer metal composites, metal or wood sheets or marine superstructure; an array of strips of polymer treated wood secured to the support by means of an adhesive; the adhesive being selected from the group consisting of: polyurethane adhesives, modified silyl polymer adhesives and epoxy resin adhesives; wherein the polymer treated wood comprises a wood species selected from the group consisting of: maple species impregnated with a wood compatible polymerisable monomer, preferably selected from furfuryl alcohol, bis hydroxymethyl furan and mixtures thereof and subsequently dried and cured. | 05-24-2012 |
20140154515 | POLYMER IMPREGNATED BAMBOO - An engineering or constructional member comprising at least two strips bonded with an adhesive; each of the strips comprises bamboo impregnated or treated with a polymer derived from one or more furfuryl alcohol resin precursors. | 06-05-2014 |